The radiolabeled compounds are preferably bile acids or bile acid derivatives.

The present invention provides topical compositions comprising fatty acid bile acid conjugates (FABACs).

Bromelain is able to act as a bile acid receptor antagonist and therefore to prevent reabsorption of bile acids by the gastrointestinal tract.

Combinations disclosed include an ileal bile acid transport inhibitor combined with a bile acid sequestrant.

Certain bile acids find use in the pharmaceutical industry.

As a result, the total bile acid pool is decreased in the Gpbar1-deficient mouse without showing any change in the fecal bile acid level.

Of the two major bile acids, cholate derivatives represent approximately eighty percent of all bile acids.

Of the two major bile acids, cholate derivatives represent approximately eighty percent of all bile acids.

Examples of the like acid usable herein include free bile acids such as ursodeoxycholic and chenodeoxycholic acids and conjugated bile acids such as tauroursodeoxycholic acid.

Vegetarians have a lower concentration of potentially carcinogenic bile acid and fewer intestinal bacteria that convert the primary bile acids into carcinogenic secondary bile acids.

The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertension.

When the bile acids combine with the amino acids glycine or taurine, they form the bile salts.

When bile acid is combined with amino acids glycine or taurine, this forms bile salts.

Certain bacterial acids in the intestines produce secondary bile acids.

In the ileum where bile acids are primarily absorbed the bile acids are predominantly conjugated.